Market Overview

UPDATE: Benchmark Initiates Symmetry Medical with Hold, $10 PT on Transitioning Business Model

Related SMA
Mid-Afternoon Market Update: Lions Gate Shares Climb on Report of Dalian Wanda Stake; Crude Oil Jumps Over 3%
Events for the Week of Nov. 17-21, 2014

Benchmark initiates its coverage on Symmetry Medical (NYSE: SMA) with a Hold rating and a price target of $10 per share.

Benchmark notes, "We are initiating coverage of Symmetry Medical (SMA) with a Hold rating and a 12-month price target of $10.00. Our twelve month price target represents 17.5 times our 2013 adjusted EPS estimate of $0.58. … We believe that SMA's business model is in transition as the company moves from an Original Equipment Manufacturer (OEM) model to more of a proprietary model by going direct to the customer through their Symmetry Surgical direct model. In 2011, we estimate that SMA generated approximately $319 million (or 89% of total revenue from their OEM division."

SMA closed at $8.61 on Wednesday.

Latest Ratings for SMA

Aug 2014Northcoast ResearchUpgradesNeutralBuy
Feb 2014WunderlichTerminatesBuy
Dec 2013WunderlichMaintainsBuy

View More Analyst Ratings for SMA
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings


Related Articles (SMA)

View Comments and Join the Discussion!

Partner Center